Date: 2014-08-20
Type of information: Product acquisition
Acquired company: Ethyol® (amifostine) from AstraZeneca (UK)
Acquiring company: Clinigen (UK)
Amount: undisclosed
Terms: * On August 20, 2014, Clinigen Group, a UK specialty global pharmaceutical company, announced the acquisition of the global rights to the oncology support therapy, Ethyol® (amifostine) from AstraZeneca. Under the terms of the agreement, Clinigen will assume full responsibility for the distribution of the product with immediate effect. AstraZeneca, working closely with Clinigen, will continue to manufacture the product whilst the NDA and Investigational New Drug (\'IND\') authorizations are transferred and the technical transfer to a third party manufacturer is completed. The acquisition will be paid for in milestone related stage payments linked to the transfer of manufacturing. The financial terms of the agreement are not disclosed.
Details: Ethyol® (amifostine) is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. In 1995, the FDA granted Ethyol® a New Drug Application (\'NDA\') and in 2013, Ethyol® revenue was approximately $4.9million. This is the second product Clinigen has acquired from AstraZeneca (the first being the anti-viral Foscavir® in 2010), and the Group\'s third oncology support product adding to Cardioxane® and Savene® bringing the Specialty Pharmaceuticals portfolio to five products in total.
Related:
